Navigation Links
Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease
Date:10/15/2007

stopped, a heart attack -- the death of a small part of the heart muscle -- may result.

In cases where drug therapy does not adequately relieve symptoms, patients have two choices: In bypass surgery, surgeons use a blood vessel harvested from the chest, leg or arm to reroute blood flow around narrowed heart arteries. In angioplasty, a catheter is used to inflate a balloon inside the plaque-narrowed artery. A mesh tube called a stent is usually inserted to keep the artery open.

For many patients, the best treatment choice is clear. For those with most extensive disease that limits blood flow in several arteries, bypass surgery is typically used. For those with the least extensive disease, less-invasive angioplasty is the standard choice. The new federal study, funded by AHRQ's Effective Health Care program and completed by the Agency's Stanford-UCSF Evidence-based Practice Center, compared the outcomes and risks of the procedures in patients with mid-range coronary disease, where either procedure might be chosen.

Among the conclusions:

-- The odds of surviving either procedure are high: about 98.5 percent of

patients survive beyond 30 days for both bypass surgery and angioplasty

(with or without a stent).

-- Long-term survival rates are likely to be comparable. About 96 percent

of patients live at least 1 year following both procedures. About 90

percent live 5 years or more. Further research is needed to clarify

survival benefits for patients at either extreme of the mid-range

spectrum.

-- About 84 percent of patients who undergo bypass surgery are free of

angina pain 1 year after the procedure, compared with about 75 percent

of patients who receive angioplasty. The difference narrows but remains

substantial 5 years after treatment.

-- About 4 percent of patients who have bypass surgery undergo a repeat

procedure within 1 year, and
'/>"/>

SOURCE Agency for Healthcare Research & Quality
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
4. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
5. ArteFill 5-Year Data to Be Presented at American Society for Aesthetic Plastic Surgery Annual Meeting
6. New Cardioprotective Drug Could Provide Boost For Post-Bypass Surgery Heart Health
7. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
8. Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery
9. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
10. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
11. Study Shows Children With ADHD Who Start on Strattera are More Likely to Change Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... third quarter 2014 financial results on Wednesday, October 29, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Wednesday, October 29 ...
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
(Date:10/17/2014)... DUBLIN , Oct. 17, 2014 ... of the "Research and Development Prospect of ... offering. Based on the 2013 ... Chinese government policies about dialysis industry and the ... in-depth research about dialysis industry segmentations. Moreover, it ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... N.J., Jan. 6, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: ... code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available ... assigned by the Centers for Medicare and Medicaid Services ... process for prescribers of KRYSTEXXA, the first and only ...
... 6, 2012 Biodel Inc. (Nasdaq: BIOD ) ... of Biodel, will present a corporate update at the 30th ... 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). ... 2012, at the Westin St. Francis Hotel in San Francisco, ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 2Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 3Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 4Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 5Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 6
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... is known for being the sole manufacturer of the stem ... to go public//. The company is slated to sell out ... with the Securities and Exchange Commission. ,Stem cells have ... raging about what this science can really offer. Controversy has ...
... mothers are demanding that they be allowed to breastfeed babies ... weight behind this proposal saying that 'women should feel confident ... Kidney's Private Member's Bill has called for a breastfeeding law ... was passed in March. In a survey by the NCT, ...
... parents of junior athletes seem to have a negative impact ... in the British Journal of Sports Medicine. ,The ... junior tennis coaches in the US, which looked at the ... The coaches had all spent an average of 17 years ...
... Minister Tony Clement has said that anti-virals will be made ... This was part of Canada’s preparation efforts to combat a ... everyone who is ill to receive treatment. A strategy is ... will get them." ,Several programs have been initiated to ...
... thrombosis (DVT) occurs when people sit in the same position ... blood causing clots in the legs//. The condition can be ... lungs, causing a pulmonary embolism. DVT which has long been ... up with a solution called flip seats which give passengers ...
... there is no evidence to blame phones towers, the chief ... that chance// is a more likely explanation for the Melbourne ... any other environmental exposure. . ,Professor Coates explained that ... there is usually no cause every time they happen though ...
Cached Medicine News:Health News:Parents of Junior Athletes do More Harm than Good 2
Scienceware® Slide Tray Cabinet holds twelve Scienceware® H44581 microscope trays horizontally in a dust free enclosure....
Compact storage cabinets for 35 mm slides....
Seasoned oak cabinet with flat sides and disappearing door...
Allows for the organized storage of blocks that have been embedded using: Tissue Cassettes, Biopsy Cassettes, Mesh Cassettes, Mega Cassettes, Processing/Embedding Cassettes and Embedding Rings....
Medicine Products: